» Articles » PMID: 27335080

The Effect of Microscopic Margin Status on Survival in Adult Retroperitoneal Soft Tissue Sarcomas

Overview
Publisher Elsevier
Date 2016 Jun 24
PMID 27335080
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Resection is the primary treatment for retroperitoneal (RP) soft tissue sarcomas (STS). Whether obtaining microscopically negative margins (R0) improves overall survival (OS) over microscopically positive margins (R1) remains unclear.

Methods: Using the National Cancer Data Base, we identified adult patients diagnosed with RP STS after R0 or R1 resection from 1998 to 2011. We used a multivariable logistic regression model to identify clinicopathologic factors associated with margin status, including radiotherapy receipt. To assess differences in OS, the log-rank test, Cox proportional hazards regression, and propensity score matching were used.

Results: We identified 4015 patients; 2593 (64.6%) underwent R0 resection and 1422 (35.4%) underwent R1 resection. The most common histology was liposarcoma (2,371, 59.1%), median age was 60 years, and median follow up was 67 months. Median OS for R0 vs. R1 patients was 92 and 70 months, respectively (log-rank p < .001). Pre-operative RT was associated with increased probability of R0 resection (68.0% vs. 57.2%, p = .012). Multivariable regression showed R0 vs. R1 resection (HR 0.70, 95% CI 0.60-0.81, p < .001) was associated with improved survival, a finding confirmed on propensity score matching. Other significant predictors of OS included low tumor grade, younger age, smaller tumor size, liposarcoma histology, and receipt of RT (HR 0.81, 95% CI 0.70-0.93, p = .016).

Conclusions: Patients who undergo R0 resection for RP STS appear to experience superior OS compared with patients who had R1 resections.

Citing Articles

Histology-Tailored Approach to Soft Tissue Sarcoma.

Gervais M, Basile G, Dulude J, Mottard S, Gronchi A Ann Surg Oncol. 2024; 31(12):7915-7929.

PMID: 39174839 DOI: 10.1245/s10434-024-15981-8.


Radiation therapy for retroperitoneal sarcoma: practice patterns in North America.

Ruff S, Heh V, Konieczkowski D, Onuma A, Dunlop H, Kim A Radiat Oncol. 2024; 19(1):38.

PMID: 38491404 PMC: 10943830. DOI: 10.1186/s13014-024-02407-8.


Surgical Management of Retroperitoneal Sarcoma.

Dominguez D, Sampath S, Agulnik M, Liang Y, Nguyen B, Trisal V Curr Oncol. 2023; 30(5):4618-4631.

PMID: 37232807 PMC: 10217420. DOI: 10.3390/curroncol30050349.


Prediction of intraoperative bleeding and blood transfusion in patients with recurrent retroperitoneal liposarcoma: a retrospective study.

Liu W, Zou B, Tang M, Li X, Huang M, Chen W Ann Transl Med. 2022; 10(18):986.

PMID: 36267785 PMC: 9577802. DOI: 10.21037/atm-22-4222.


Retroperitoneal Sarcomas: a Current Review on Management.

Patkar S, Kattepur A, Khanna N, Bajpai J Indian J Surg Oncol. 2022; 13(3):542-558.

PMID: 36187536 PMC: 9515254. DOI: 10.1007/s13193-022-01520-y.